Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Alpine Immune Sciences, Inc.

SG&A Expenses: A Decade of Growth and Strategy

__timestampAlpine Immune Sciences, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014228770938783000000
Thursday, January 1, 2015684400042585000000
Friday, January 1, 2016858600045702000000
Sunday, January 1, 2017607900046372000000
Monday, January 1, 2018836200046910000000
Tuesday, January 1, 2019946700048890000000
Wednesday, January 1, 20201089900050129000000
Friday, January 1, 20211456000054559000000
Saturday, January 1, 20221796800062081000000
Sunday, January 1, 202322222000105931000000
Monday, January 1, 202477201000000
Loading chart...

Data in motion

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical and biotechnology sectors, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Dr. Reddy's Laboratories Limited and Alpine Immune Sciences, Inc. from 2014 to 2023.

Dr. Reddy's Laboratories, a global pharmaceutical giant, has consistently demonstrated robust financial management, with SG&A expenses peaking at approximately 106 billion in 2023, a staggering 173% increase from 2014. In contrast, Alpine Immune Sciences, a burgeoning biotech firm, saw its SG&A expenses grow by nearly 872% over the same period, reaching around 22 million in 2023.

This stark contrast highlights the differing scales and growth trajectories of these companies. While Dr. Reddy's maintains a steady expansion, Alpine's rapid increase in expenses reflects its aggressive growth strategy in the competitive biotech landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025